Your browser doesn't support javascript.
loading
Temporal trends in lung cancer survival: a population-based study.
Löfling, Lukas; Bahmanyar, Shahram; Kieler, Helle; Lambe, Mats; Wagenius, Gunnar.
Afiliación
  • Löfling L; Department of Research, Cancer Registry of Norway, Oslo, Norway.
  • Bahmanyar S; Department of Medicine - Solna, Karolinska Institutet, Centre for Pharmacoepidemiology, Solna, Sweden.
  • Kieler H; Department of Medicine - Solna, Karolinska Institutet, Centre for Pharmacoepidemiology, Solna, Sweden.
  • Lambe M; Department of Medicine - Solna, Karolinska Institutet, Centre for Pharmacoepidemiology, Solna, Sweden.
  • Wagenius G; Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden.
Acta Oncol ; 61(5): 625-631, 2022 May.
Article en En | MEDLINE | ID: mdl-34889167
ABSTRACT

BACKGROUND:

Lung cancer is the number one cancer-related cause of death in Sweden and worldwide. In most countries, five-year survival estimates vary between 10% and 20% with evidence of improved survival over time. Over the last decades, the management of lung cancer has changed including the introduction of national guidelines, new diagnostic procedures and treatments. This study aimed to investigate temporal trends in lung cancer survival both overall and in subgroups defined by established prognostic factors (i.e., sex, stage, histopathology and smoking history). MATERIALS AND

METHODS:

We estimated one-, two-, and five-year relative survival, and excess mortality, in patients diagnosed with squamous cell carcinoma or adenocarcinoma of the lung between 1995 and 2016 in Sweden. We used population-based information available in a national lung cancer research database (LCBaSe) generated by cross-linkage between the Swedish National Lung Cancer Register and several Swedish health and sociodemographic registers.

RESULTS:

We included 36,935 patients diagnosed with squamous cell carcinoma or adenocarcinoma of the lung between 1995 and 2016. The overall one-, two- and five-year survival estimates increased between 1995 and 2016, from 38% to 53%, 21% to 37%, and 14% to 24%, respectively. Over the study period, we also found improved survival in subgroups, for example in patients with stages III-IV disease, patients with adenocarcinoma, and never-smokers. The excess mortality decreased over the study period, both overall and in all subgroups.

CONCLUSION:

Lung cancer survival increased over time in the overall lung cancer population. Of special note was evidence of improved survival in patients with stage IV disease. Our results corroborate a previously observed global trend of improved survival in patients with lung cancer.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Adenocarcinoma / Neoplasias Pulmonares Tipo de estudio: Guideline / Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Acta Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Noruega

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Adenocarcinoma / Neoplasias Pulmonares Tipo de estudio: Guideline / Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Acta Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Noruega
...